9DHY
Structure of SARS-CoV-2 spike in complex with antibody Fab COVIC-154
Summary for 9DHY
| Entry DOI | 10.2210/pdb9dhy/pdb |
| EMDB information | 46892 |
| Descriptor | Antibody Fab COVIC-154 Heavy Chain, Antibody Fab COVIC-154 Light Chain, Spike glycoprotein, ... (5 entities in total) |
| Functional Keywords | viral protein, glycoprotein, immune system, antibody, sars-cov-2, covid, viral protein-immune system complex, coronavirus, antiviral protein, viral protein/immune system |
| Biological source | Homo sapiens More |
| Total number of polymer chains | 9 |
| Total formula weight | 486037.06 |
| Authors | |
| Primary citation | Schendel, S.L.,Yu, X.,Halfmann, P.J.,Mahita, J.,Ha, B.,Hastie, K.M.,Li, H.,Bedinger, D.,Troup, C.,Li, K.,Kuzmina, N.,Torrelles, J.B.,Munt, J.E.,Maddocks, M.,Osei-Twum, M.,Callaway, H.M.,Reece, S.,Palser, A.,Kellam, P.,Dennison, S.M.,Huntwork, R.H.C.,Horn, G.Q.,Abraha, M.,Feeney, E.,Martinez-Sobrido, L.,Pino, P.A.,Hicks, A.,Ye, C.,Park, J.G.,Maingot, B.,Periasamy, S.,Mallory, M.,Scobey, T.,Lepage, M.N.,St-Amant, N.,Khan, S.,Gambiez, A.,Baric, R.S.,Bukreyev, A.,Gagnon, L.,Germann, T.,Kawaoka, Y.,Tomaras, G.D.,Peters, B.,Saphire, E.O. A global collaboration for systematic analysis of broad-ranging antibodies against the SARS-CoV-2 spike protein. Cell Rep, 44:115499-115499, 2025 Cited by PubMed Abstract: The Coronavirus Immunotherapeutic Consortium (CoVIC) conducted side-by-side comparisons of over 400 anti-SARS-CoV-2 spike therapeutic antibody candidates contributed by large and small companies as well as academic groups on multiple continents. Nine reference labs analyzed antibody features, including in vivo protection in a mouse model of infection, spike protein affinity, high-resolution epitope binning, ACE-2 binding blockage, structures, and neutralization of pseudovirus and authentic virus infection, to build a publicly accessible dataset in the database CoVIC-DB. High-throughput, high-resolution binning of CoVIC antibodies defines a broad and predictive landscape of antibody epitopes on the SARS-CoV-2 spike protein and identifies features associated with durable potency against multiple SARS-CoV-2 variants of concern and high in vivo efficacy. Results of the CoVIC studies provide a guide for selecting effective and durable antibody therapeutics and for immunogen design as well as providing a framework for rapid response to future viral disease outbreaks. PubMed: 40184253DOI: 10.1016/j.celrep.2025.115499 PDB entries with the same primary citation |
| Experimental method | ELECTRON MICROSCOPY (2.7 Å) |
Structure validation
Download full validation report
